Letters to the Editor
Early Access
https://doi.org/10.4081/dr.2026.10823

Efficacy and safety of mogamulizumab in Sézary syndrome with concomitant Crohn’s disease

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 12 May 2026
32
Views
15
Downloads
Mogamulizumab, Sézary syndrome, Crohn’s disease

Authors

Cosimo Di Raimondo
cosimodiraimondo@gmail.com
Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome, Italy.
Edoardo Mortato
Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy.
Pier Paolo Di Domenico
Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy.
Luca Bianchi
Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome; Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy.
Marco Galluzzo
Dermatology Unit, Fondazione Policlinico “Tor Vergata”, Rome; Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy.

Dear Editor,

Mogamulizumab is a humanized, defucosylated monoclonal antibody targeting CC chemokine receptor 4 (CCR4), expressed on malignant T cells in cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides and Sézary syndrome. By enhancing antibody-dependent cellular cytotoxicity, mogamulizumab selectively depletes CCR4-positive malignant lymphocytes and has demonstrated significant clinical activity in advanced CTCL, including in patients refractory to multiple prior therapies. [...]

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Fernández-Guarino M, Ortiz P, Gallardo F, Llamas-Velasco M. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review. Int J Mol Sci 2024;25:2203.
2. Choi SB, Lee HT, Gu N, et al. Structural Insights into the ADCC Mechanism and Resistance of Mogamulizumab, a First-in-Class Anti-CCR4 Therapy for Cutaneous T Cell Lymphoma. Int J Mol Sci 2025;26:5500.
3. Martinez XU, Di Raimondo C, Abdulla FR, et al. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome. Best Pract Res Clin Haematol 2019;32:239-52.
4. Kim YH, Bagot M, Pinter-Brown L, et al; MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, openlabel, randomised, controlled phase 3 trial. Lancet Oncol 2018;19:1192-204. Erratum in: Lancet Oncol 2018;19:e581.
5. Blanchard G, Blanchard M, Bernard P, et al. Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management. JAAD Case Rep 2024;54:23-6.
6. Kunkel EJ, Boisvert J, Murphy K, et al. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am J Pathol 2002;160:347-55.
7. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999;400:776-80.

How to Cite



1.
Di Raimondo C, Mortato E, Di Domenico PP, Bianchi L, Galluzzo M. Efficacy and safety of mogamulizumab in Sézary syndrome with concomitant Crohn’s disease. Dermatol Reports [Internet]. 2026 May 12 [cited 2026 May 16];. Available from: https://journals.pagepress.net/dr/article/view/10823
Copyright (c) 2026 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.